DGCI Approves SII's Phase 2 And 3 Human Trials For Oxford University's COVID-19 Vaccine Candidate

The Drugs Controller General of India (DGCI) has approved the Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials of the University of Oxford's COVID-19 vaccine candidate, reports PTI. Officials told PTI that SII has submitted a revised proposal on July 29 after the Subject Expert Committee asked for revisions in its previous proposal. 1,600 people over 18 years of age will participate in the trials across 17 selected sites in India.